Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges

Synchrony Financial is executing a strategic balancing act in the current economic climate. The U.S. financial services provider continues to forge significant new alliances, particularly within two key industries, even as its overall credit volumes experience a period of contraction. The central question for investors is whether these partnerships can ultimately reverse the trend of declining loan growth.

Credit Metrics and Risk Management

The company currently faces headwinds in its core lending business. Outstanding loan balances fell by 2.2% in August compared to the previous year. This decline is attributed to a deliberate strategic pivot toward serving more “Super-Prime” customers, who typically exhibit stronger credit profiles and faster repayment cycles. Countering this trend are notably improving risk metrics. Throughout 2025, the company has successfully reduced both its charge-off rates and delinquencies. A clear signal of effective risk control was the release of $265 million in reserves during the second quarter.

Healthcare Sector Expansion Through Audible Alliance

A major strategic development was the recently announced partnership with Audibel, a leading hearing health provider. Effective September 17, Synchrony’s CareCredit card became the exclusive financing solution across all Audibel locations and its online platform. This agreement allows patients to finance hearing tests, devices, and related accessories. The move significantly bolsters Synchrony’s Health & Wellness platform and provides access to new growth channels within the valuable healthcare market.

The Long-Term Potential of the Walmart Partnership

Potentially more transformative is the newly forged alliance with retail titan Walmart. Their OnePay partnership program is scheduled to launch in the fall of 2025, with its full impact not anticipated until 2026. Chief Financial Officer Brian Wenzel recently characterized the program as having the potential to become a “Top 5 or Top 10” initiative for Synchrony but cautioned against expecting significant near-term benefits. The company’s management has indicated that no material effect on growth rates is projected for 2025.

Should investors sell immediately? Or is it worth buying Synchrony?

Analyst Sentiment and Valuation

Market analysts maintain a cautiously optimistic outlook. The current consensus recommendation stands at “Moderate Buy,” accompanied by an average price target of approximately $74 per share. However, estimates reveal a wide range from $60 to $100, highlighting significant market uncertainty. Key fundamental indicators suggest the stock may be undervalued, trading at a P/E ratio of 9.1 and delivering a return on equity of 21%. Furthermore, Synchrony has demonstrated a commitment to shareholder returns, maintaining an unbroken decade-long streak of dividend payments.

Upcoming Q3 Earnings and Strategic Focus

All attention now turns to the quarterly results scheduled for release on October 15. Investors will scrutinize the company’s progress toward its full-year expected EPS of $7.67. Of particular importance will be any commentary confirming CFO Wenzel’s forecast for a net interest margin improvement in the second half of the year, alongside updates on the long-term goal of achieving 10% receivables growth.

Synchrony’s strategy remains firmly centered on organic growth, supplemented by consistent dividends and share repurchases. While its new strategic partnerships lay a solid foundation for future expansion, the timeline for these ventures to materially influence performance remains the critical unknown for the investment community.